Market Scope (@MarketScope_LLC) header
Market Scope (@MarketScope_LLC) profile picture

Market Scope

@MarketScope_LLC
 St Louis, MO
market-scope.com
Joined December 2014
  • Tweets4.3K
  • Following620
  • Followers554
104Media
Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland: bit.ly/4yHCo6E

Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland | Market Scope

Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those...

market-scope.com
11
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu: bit.ly/4jHsWMQ

EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu | Market Scope

EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...

market-scope.com
12
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia: bit.ly/4zdiyRZ

US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia | Market Scope

Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the...

market-scope.com
15
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops: bit.ly/4ifhtS7

US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops | Market Scope

Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours,...

market-scope.com
10
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision: bit.ly/4jCW0Fa

Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision | Market Scope

Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo...

market-scope.com
5
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million: bit.ly/47M9M15

Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million | Market Scope

Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make...

market-scope.com
13
HelpMeSee Names Former Test Pilot Doug May as President and CEO: bit.ly/484psga

HelpMeSee Names Former Test Pilot Doug May as President and CEO | Market Scope

Global nonprofit group HelpMeSee announced Oct. 1 that it had appointed Doug May as president and chief executive officer. May joined HelpMeSee in 2025 as chief operating officer. He previously...

market-scope.com
10
Corza Medical Launches Expanded Single-Use Custom Packs: bit.ly/47poUkX

Corza Medical Launches Expanded Single-Use Custom Packs | Market Scope

Corza Medical, of Boulder, Colorado, announced Oct. 10 the launch of its expanded Blink single-use custom surgical packs. The company also debuted a new automated manufacturing process for its...

market-scope.com
16
Visara Licenses Topical Neurotrophic Keratitis Candidate from China’s Hiteck: bit.ly/482COcR

Visara Licenses Topical Neurotrophic Keratitis Candidate from China’s Hiteck | Market Scope

Visara, the ophthalmic subsidiary of NovaBridge Biosciences, announced Oct. 13 that it had licensed a topical candidate targeting neurotrophic keratitis (NK) from China’s Wuhan Hiteck Biopharma....

market-scope.com
9
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027: bit.ly/4838MFS

US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027 | Market Scope

Genentech, a member of the Roche group, reported Oct. 10 that the US FDA had accepted the biologics license application (BLA) for vamikibart, an intravitreal IL-6 inhibitor candidate for uveitic...

market-scope.com
15
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over: bit.ly/4jphEwx
17
Alvotech, Advanz Submit Marketing Application to EMA for High-Dose Aflibercept Biosimilar: bit.ly/4i21VBe
15
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED: bit.ly/4it47D4

US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED | Market Scope

Genentech and its parent, Roche, announced Oct. 16 that the US FDA had approved Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED). It’s the first at-home,...

market-scope.com
14
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate: bit.ly/4yiDN3a

US FDA Gives Green Light to Trial of Surrozen’s DME Candidate | Market Scope

Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonist...

market-scope.com
12
Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings: bit.ly/4hXg0js

Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings | Market Scope

Three scientists who helped develop optogenetics received the 2026 Nobel Prize in Physiology or Medicine on Oct. 5. They are Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute in...

market-scope.com
12
VEO Ophthalmics to Market the VitaPixel Visualization System for Slit Lamps: bit.ly/4ymvBPB

VEO Ophthalmics to Market the VitaPixel Visualization System for Slit Lamps | Market Scope

VEO Ophthalmics and VitaPixel announced a collaboration Oct. 2 under which VEO will market the VitaPixel SVS, a stereoscopic digital visualization system for slit lamps. The VitaPixel SVS combines...

market-scope.com
9
Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority Review: bit.ly/47TELbu

Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority...

Nanoscope Therapeutics announced Oct. 1 that regulators in Japan had accepted the company’s new drug application for Mogenry, an optogenetic gene therapy candidate targeting inherited retinal...

market-scope.com
6
Study Indicates that Circadian Rhythm and Light May Affect IOP: bit.ly/4jW64cj

Study Indicates that Circadian Rhythm and Light May Affect IOP | Market Scope

Researchers at the University of South Florida (USF) reported Sept. 30 that continuously monitoring intraocular pressure (IOP) in a rat model showed that eye pressure follows a daily rhythm, consis...

market-scope.com
9
Sagent Pharmaceuticals Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US: bit.ly/4s194WV

Sagent Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US | Market Scope

Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen (indocyanine green injection). Sagent said Zyogreen is the first and only FDA-approved ready-to-use...

market-scope.com
10
Carrot, Maker of VR Visual Field Testing, Acquires IOL Simulation Developer GreenMan: bit.ly/4k2aEps

Carrot, Maker of VR Visual Field Testing, Acquires IOL Simulation Developer GreenMan | Market Scope

Carrot (formerly Virtual Field) reported Oct. 9 that it had agreed to acquire GreenMan Vision, of West Fargo, North Dakota, and its InSightVR IOL simulator. No financial details were provided. The...

market-scope.com
13
Load more